$87 Million
Joint Bookrunner
Initial Public Offering
June 2012
$410 Million
Exclusive Financial Advisor
Sale of Hemostasis Portfolio to Mallinckrodt plc
February 2016
$400 Million
Co-Manager
Convertible Senior Note Offering
January 2015
$201 Million
Joint Bookrunner
Follow-On
August 2013
$115M + Option to Purchase
Exclusive Financial Advisor
Collaboration with BMS for Recothrom Bristol-Myers Squibb
December 2012
$280 Million
Exclusive Financial Advisor
GSK Offering of Senior Notes Exchangeable into Theravance Shares
June 2020
$230 Million
Joint Bookrunner
Convertible Notes
October 2016
$115 Million
Joint Bookrunner
Follow-On
October 2016
$115 Million
Joint Bookrunner
Follow-On
April 2016
$99 Million
Joint Bookrunner
Follow-On
March 2010
$101 Million
Joint Bookrunner
Follow-On
June 2021
UNDISCLOSED
Exclusive Financial Advisor
Sale to Asahi/Zoll Medical
June 2019